Maintenance therapy for CTCL: importance for prevention of disease progression

Emily R. Gordon; Megan H. Trager; Bradley D. Kwinta; Connor J. Stonesifer; Kaitlyn J. Lee; Oluwaseyi Adeuyan; Brigit A. Lapolla; Oleg E. Akilov; Paula A. Enz; Emmanuella Guenova; Pablo L. Ortiz-Romero; Evangelia Papadavid; Pietro Quaglino; Sima Rozati; Julia J. Scarisbrick; Thomas Litman; Larisa J. Geskin

doi:10.1080/10428194.2024.2376164

Maintenance therapy for CTCL: importance for prevention of disease progression

Emily R. Gordon, Megan H. Trager, Bradley D. Kwinta, Connor J. Stonesifer, Kaitlyn J. Lee, Oluwaseyi Adeuyan, Brigit A. Lapolla, Oleg E. Akilov, Paula A. Enz, Emmanuella Guenova, Pablo L. Ortiz-Romero, Evangelia Papadavid, Pietro Quaglino, Sima Rozati, Julia J. Scarisbrick, Thomas Litman, Larisa J. Geskin

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

There are no established maintenance protocols for cutaneous lymphomas. We aim to determine patient treatments and outcomes during the COVID-19 pandemic in order to uncover the most effective maintenance protocols for cutaneous lymphomas and impact of treatment interruption. Data was collected retrospectively from nine international institutions, including 149 patients. Younger patients had earlier stages of disease and were most frequently treated with skin-directed therapies including topical steroids, mechlorethamine gel, and phototherapy. Treatment interruption varied by treatment type and stage, with patients on topical therapies and earlier stages of disease being least likely to experience interruption. Treatment interruption was significantly associated with progression of disease and worse outcomes, with twice as many patients progressing who had interruption compared to those without interruption. This study may demonstrate the significance of continuous maintenance therapies, even in younger patients with early stages of disease.

Original language	English (US)
Pages (from-to)	1883-1890
Number of pages	8
Journal	Leukemia and Lymphoma
Volume	65
Issue number	12
DOIs	https://doi.org/10.1080/10428194.2024.2376164
State	Published - 2024

Keywords

CTCL
Maintenance therapy
covid-19
cutaneous lymphoma
early-stage
treatments

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428194.2024.2376164

Cite this

Gordon, E. R., Trager, M. H., Kwinta, B. D., Stonesifer, C. J., Lee, K. J., Adeuyan, O., Lapolla, B. A., Akilov, O. E., Enz, P. A., Guenova, E., Ortiz-Romero, P. L., Papadavid, E., Quaglino, P., Rozati, S., Scarisbrick, J. J., Litman, T., & Geskin, L. J. (2024). Maintenance therapy for CTCL: importance for prevention of disease progression. Leukemia and Lymphoma, 65(12), 1883-1890. https://doi.org/10.1080/10428194.2024.2376164

Gordon, ER, Trager, MH, Kwinta, BD, Stonesifer, CJ, Lee, KJ, Adeuyan, O, Lapolla, BA, Akilov, OE, Enz, PA, Guenova, E, Ortiz-Romero, PL, Papadavid, E, Quaglino, P, Rozati, S, Scarisbrick, JJ, Litman, T & Geskin, LJ 2024, 'Maintenance therapy for CTCL: importance for prevention of disease progression', Leukemia and Lymphoma, vol. 65, no. 12, pp. 1883-1890. https://doi.org/10.1080/10428194.2024.2376164

@article{8cbbb60e61ab433085c651900b21f828,

title = "Maintenance therapy for CTCL: importance for prevention of disease progression",

abstract = "There are no established maintenance protocols for cutaneous lymphomas. We aim to determine patient treatments and outcomes during the COVID-19 pandemic in order to uncover the most effective maintenance protocols for cutaneous lymphomas and impact of treatment interruption. Data was collected retrospectively from nine international institutions, including 149 patients. Younger patients had earlier stages of disease and were most frequently treated with skin-directed therapies including topical steroids, mechlorethamine gel, and phototherapy. Treatment interruption varied by treatment type and stage, with patients on topical therapies and earlier stages of disease being least likely to experience interruption. Treatment interruption was significantly associated with progression of disease and worse outcomes, with twice as many patients progressing who had interruption compared to those without interruption. This study may demonstrate the significance of continuous maintenance therapies, even in younger patients with early stages of disease.",

keywords = "CTCL, Maintenance therapy, covid-19, cutaneous lymphoma, early-stage, treatments",

author = "Gordon, {Emily R.} and Trager, {Megan H.} and Kwinta, {Bradley D.} and Stonesifer, {Connor J.} and Lee, {Kaitlyn J.} and Oluwaseyi Adeuyan and Lapolla, {Brigit A.} and Akilov, {Oleg E.} and Enz, {Paula A.} and Emmanuella Guenova and Ortiz-Romero, {Pablo L.} and Evangelia Papadavid and Pietro Quaglino and Sima Rozati and Scarisbrick, {Julia J.} and Thomas Litman and Geskin, {Larisa J.}",

note = "Publisher Copyright: {\textcopyright} 2024 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2024",

doi = "10.1080/10428194.2024.2376164",

language = "English (US)",

volume = "65",

pages = "1883--1890",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "12",

}

TY - JOUR

T1 - Maintenance therapy for CTCL

T2 - importance for prevention of disease progression

AU - Gordon, Emily R.

AU - Trager, Megan H.

AU - Kwinta, Bradley D.

AU - Stonesifer, Connor J.

AU - Lee, Kaitlyn J.

AU - Adeuyan, Oluwaseyi

AU - Lapolla, Brigit A.

AU - Akilov, Oleg E.

AU - Enz, Paula A.

AU - Guenova, Emmanuella

AU - Ortiz-Romero, Pablo L.

AU - Papadavid, Evangelia

AU - Quaglino, Pietro

AU - Rozati, Sima

AU - Scarisbrick, Julia J.

AU - Litman, Thomas

AU - Geskin, Larisa J.

PY - 2024

Y1 - 2024

N2 - There are no established maintenance protocols for cutaneous lymphomas. We aim to determine patient treatments and outcomes during the COVID-19 pandemic in order to uncover the most effective maintenance protocols for cutaneous lymphomas and impact of treatment interruption. Data was collected retrospectively from nine international institutions, including 149 patients. Younger patients had earlier stages of disease and were most frequently treated with skin-directed therapies including topical steroids, mechlorethamine gel, and phototherapy. Treatment interruption varied by treatment type and stage, with patients on topical therapies and earlier stages of disease being least likely to experience interruption. Treatment interruption was significantly associated with progression of disease and worse outcomes, with twice as many patients progressing who had interruption compared to those without interruption. This study may demonstrate the significance of continuous maintenance therapies, even in younger patients with early stages of disease.

AB - There are no established maintenance protocols for cutaneous lymphomas. We aim to determine patient treatments and outcomes during the COVID-19 pandemic in order to uncover the most effective maintenance protocols for cutaneous lymphomas and impact of treatment interruption. Data was collected retrospectively from nine international institutions, including 149 patients. Younger patients had earlier stages of disease and were most frequently treated with skin-directed therapies including topical steroids, mechlorethamine gel, and phototherapy. Treatment interruption varied by treatment type and stage, with patients on topical therapies and earlier stages of disease being least likely to experience interruption. Treatment interruption was significantly associated with progression of disease and worse outcomes, with twice as many patients progressing who had interruption compared to those without interruption. This study may demonstrate the significance of continuous maintenance therapies, even in younger patients with early stages of disease.

KW - CTCL

KW - Maintenance therapy

KW - covid-19

KW - cutaneous lymphoma

KW - early-stage

KW - treatments

UR - http://www.scopus.com/inward/record.url?scp=85197717512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85197717512&partnerID=8YFLogxK

U2 - 10.1080/10428194.2024.2376164

DO - 10.1080/10428194.2024.2376164

M3 - Article

C2 - 38975910

AN - SCOPUS:85197717512

SN - 1042-8194

VL - 65

SP - 1883

EP - 1890

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 12

ER -

Maintenance therapy for CTCL: importance for prevention of disease progression

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this